oral semaglutide cardiovascular outcomes soul trial results 2024 2025 PDF) and in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the Randomized Canadian Perspectives 2025 Whiteboard on

This was a much too small study, which they acknowledge, to assess these rare but very important patient oriented safety outcomes

PlexusDx encourages patients to document symptom changes and communicate them to their healthcare provider immediately

However, coordinated care is essential: regular thyroid function monitoring should continue, and significant weight loss may require levothyroxine dose adjustments

According to published research, it was developed in the 1990s and has been studied primarily in animal models and limited human trials

Many people tend to regain some weight after stopping semaglutide, which is why some continue to take it long-term